In:
American Journal of Physiology-Gastrointestinal and Liver Physiology, American Physiological Society, Vol. 273, No. 5 ( 1997-11-01), p. G1031-G1035
Abstract:
The aim of this study was to look at the role of α 1 -acid glycoprotein as a natural anti-inflammatory agent with particular respect to its antineutrophil and anticomplement activity. A recombinantly engineered form of sialyl Lewis x (sLe x )-bearing α 1 -acid glycoprotein (sAGP) was administered intravenously to pentobarbital-anesthetized rats after 50 min of intestinal ischemia just before 4 h of reperfusion. A non-sLe x -bearing form of AGP (nsAGP) was used as control. sAGP-treated animals had a 62% reduction ( P 〈 0.05) in remote lung injury, assessed by 125 I-albumin permeability, compared with those treated with nsAGP (permeability index of 3.61 ± 0.15 × 10 −3 and 5.18 ± 0.67 × 10 −3 , respectively). There was a reduction in pulmonary myeloperoxidase levels in sAGP-treated rats compared with nsAGP-treated rats. Complement-dependent intestinal injury, assessed by 125 I-albumin permeability was reduced by 28% ( P 〈 0.05) in animals treated with sAGP (7.58 ± 0.63) compared with those treated with nsAGP (10.4 ± 0.54). We conclude that sAGP ameliorates both complement- and neutrophil-mediated injuries.
Type of Medium:
Online Resource
ISSN:
0193-1857
,
1522-1547
DOI:
10.1152/ajpgi.1997.273.5.G1031
Language:
English
Publisher:
American Physiological Society
Publication Date:
1997
detail.hit.zdb_id:
1477329-6
SSG:
12
